Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

References

• FriedmanDSO’ColmainBJMunozBEye Diseases Prevalence Research GroupPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• van LeeuwenRKlaverCCVingerlingJRHofmanAde JongPTThe risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam studyArch Ophthalmol2003121451952612695249
   PubMed Web of Science ®Google Scholar
• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• BarbazettoIASarojNShapiroHWongPHoACFreundKBIncidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trialsAm J Ophthalmol20101496939946.e93120378094
   PubMed Web of Science ®Google Scholar
• ClemonsTEMiltonRCKleinRSeddonJMFerrisFL3rdAge-Related Eye Disease Study Research GroupRisk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19Ophthalmology2005112453353915808240
   PubMed Web of Science ®Google Scholar
• VirgiliGBiniALaser photocoagulation for neovascular age-related macular degenerationCochrane Database Syst Rev20073CD00476317636773
   PubMed Web of Science ®Google Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP reportArch Ophthalmol1999117101329134510532441
   PubMed Web of Science ®Google Scholar
• EandiCMGiansantiFVirgiliGMacular translocation for neovascular age-related macular degenerationCochrane Database Syst Rev20084CD00692818843739
   PubMed Web of Science ®Google Scholar
• SolomonSDLindsleyKVedulaSSKrzystolikMGHawkinsBSAnti-vascular endothelial growth factor for neovascular age-related macular degenerationCochrane Database Syst Rev20148CD00513925170575
   PubMed Web of Science ®Google Scholar
• SingermanLJMasonsonHPatelMPegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trialBr J Ophthalmol200892121606161118614570
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• GroupCRMartinDFMaguireMGRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCAIVAN Study InvestigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialLancet201338299001258126723870813
   PubMed Web of Science ®Google Scholar
• DixonJAOliverSCOlsonJLMandavaNVEGF trap-eye for the treatment of neovascular age-related macular degenerationExpert Opin Investig Drugs2009181015731580
   PubMed Web of Science ®Google Scholar
• SemeraroFMorescalchiFDuseSParmeggianiFGambicortiECostagliolaCAflibercept in wet AMD: specific role and optimal useDrug Des Devel Ther20137711722
   PubMed Web of Science ®Google Scholar
• BazanNGHomeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor LectureInvest Ophthalmol Vis Sci2007481148664881 biography 4864–486517962433
   PubMed Web of Science ®Google Scholar
• Saint-GeniezMKuriharaTSekiyamaEMaldonadoAED’AmorePAAn essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProc Natl Acad Sci U S A200910644187511875619841260
   PubMed Web of Science ®Google Scholar
• BaiYMaJXGuoJMuller cell-derived VEGF is a significant contributor to retinal neovascularizationJ Pathol2009219444645419768732
   PubMed Web of Science ®Google Scholar
• AblonczyZDahroujMMarnerosAGProgressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levelsFASEB J20142852369237924558195
   PubMed Web of Science ®Google Scholar
• YangXMYafaiYWiedemannPHypoxia-induced upregulation of pigment epithelium-derived factor by retinal glial (Muller) cellsJ Neurosci Res201290125726621922517
   PubMed Web of Science ®Google Scholar
• ShirinifardAGlazierJASwatMAdhesion failures determine the pattern of choroidal neovascularization in the eye: a computer simulation studyPLoS Comput Biol201285e100244022570603
   PubMed Web of Science ®Google Scholar
• CampochiaroPASolowayPRyanSJMillerJWThe pathogenesis of choroidal neovascularization in patients with age-related macular degenerationMol Vis199953410562658
   PubMed Web of Science ®Google Scholar
• FunkMKarlDGeorgopoulosMNeovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumabOphthalmology2009116122393239919815292
   PubMed Web of Science ®Google Scholar
• MuetherPSNeuhannIBuhlCHermannMMKirchhofBFauserSIntraocular growth factors and cytokines in patients with dry and neovascular age-related macular degenerationRetina20133391809181423492946
   PubMed Web of Science ®Google Scholar
• GirmensJFSahelJAMarazovaKDry age-related macular degeneration: a currently unmet clinical needIntractable Rare Dis Res20121310311425343081
   PubMedGoogle Scholar
• SingerMAdvances in the management of macular degenerationF1000Prime Rep201462924860651
   PubMedGoogle Scholar
• GrisantiSTatarOThe role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degenerationProg Retin Eye Res200827437239018621565
   PubMed Web of Science ®Google Scholar
• JoNMailhosCJuMInhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularizationAm J Pathol200616862036205316723717
   PubMed Web of Science ®Google Scholar
• FerrariGCookBDTerushkinVPintucciGMignattiPTransforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosisJ Cell Physiol2009219244945819180561
   PubMed Web of Science ®Google Scholar
• OgataNMatsushimaMTakadaYExpression of basic fibroblast growth factor mRNA in developing choroidal neovascularizationCurr Eye Res19961510100810188921239
   PubMed Web of Science ®Google Scholar
• SkeieJMZengSFaidleyEAMullinsRFAngiogenin in age-related macular degenerationMol Vis20111757658221364907
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neo-vascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar
• FrankRNAminRHEliottDPuklinJEAbramsGWBasic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranesAm J Ophthalmol199612233934038794712
   PubMed Web of Science ®Google Scholar
• TatarOShinodaKAdamAExpression of endostatin in human choroidal neovascular membranes secondary to age-related macular degenerationExp Eye Res200683232933816584730
   PubMed Web of Science ®Google Scholar
• WangSSorensonCMSheibaniNLack of thrombospondin 1 and exacerbation of choroidal neovascularizationArch Ophthalmol2012130561562022232368
   PubMedGoogle Scholar
• MoriKDuhEGehlbachPPigment epithelium-derived factor inhibits retinal and choroidal neovascularizationJ Cell Physiol2001188225326311424092
   PubMed Web of Science ®Google Scholar
• GundaVSudhakarYARegulation of tumor angiogenesis and choroidal neovascularization by endogenous angioinhibitorsJ Cancer Sci Ther201351241742625258675
   PubMedGoogle Scholar
• DasAMcGuirePGRetinal and choroidal angiogenesis: pathophysiology and strategies for inhibitionProg Retin Eye Res200322672174814575722
   PubMed Web of Science ®Google Scholar
• WeisSMChereshDATumor angiogenesis: molecular pathways and therapeutic targetsNat Med201117111359137022064426
   PubMed Web of Science ®Google Scholar
• YannuzziLANegraoSIidaTRetinal angiomatous proliferation in age-related macular degeneration. 2001Retina201232Suppl 141643422451953
   PubMedGoogle Scholar
• YannuzziLAFreundKBTakahashiBSReview of retinal angiomatous proliferation or type 3 neovascularizationRetina200828337538418327130
   PubMed Web of Science ®Google Scholar
• JungJJChenCYMrejenSThe incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degenerationAm J Ophthalmol20141584769779.e76225034111
   PubMed Web of Science ®Google Scholar
• GassJDStereoscopic Atlas of Macular Diseases4th edSt Louis, MOMosby1997
   Google Scholar
• FreundKBZweifelSAEngelbertMDo we need a new classification for choroidal neovascularization in age-related macular degeneration?Retina20103091333134920924258
   PubMed Web of Science ®Google Scholar
• VinoresSAYoussriAILunaJDUpregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal diseaseHistol Histopathol1997121991099046048
   PubMed Web of Science ®Google Scholar
• Pe’erJFolbergRItinAGnessinHHemoIKeshetEVascular endothelial growth factor upregulation in human central retinal vein occlusionOphthalmology199810534124169499769
   PubMed Web of Science ®Google Scholar
• WeissKSteinbruggerIWegerMIntravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumabEye (Lond)20092391812181819169227
   PubMed Web of Science ®Google Scholar
• SkoldMKvon GerttenCSandberg-NordqvistACMathiesenTHolminSVEGF and VEGF receptor expression after experimental brain contusion in ratJ Neurotrauma200522335336715785231
   PubMed Web of Science ®Google Scholar
• NozakiMRaislerBJSakuraiEDrusen complement components C3a and C5a promote choroidal neovascularizationProc Natl Acad Sci U S A200610372328233316452172
   PubMed Web of Science ®Google Scholar
• SpaideRFHo-SpaideWCBrowneRWArmstrongDCharacterization of peroxidized lipids in Bruch’s membraneRetina199919214114710213241
   PubMed Web of Science ®Google Scholar
• McLeodDSGrebeRBhuttoIMergesCBabaTLuttyGARelationship between RPE and choriocapillaris in age-related macular degenerationInvest Ophthalmol Vis Sci200950104982499119357355
   PubMed Web of Science ®Google Scholar
• HolmesDIZacharyIThe vascular endothelial growth factor (VEGF) family: angiogenic factors in health and diseaseGenome Biol20056220915693956
   PubMed Web of Science ®Google Scholar
• IyerSAcharyaKRTying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokinesFEBS J2011278224304432221917115
   PubMed Web of Science ®Google Scholar
• NeufeldGCohenTGengrinovitchSPoltorakZVascular endothelial growth factor (VEGF) and its receptorsFASEB J19991319229872925
   PubMed Web of Science ®Google Scholar
• WeiMHPopescuNCLermanMIMerrillMJZimonjicDBLocalization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12Hum Genet19969767947978641698
   PubMed Web of Science ®Google Scholar
• TischerEMitchellRHartmanTThe human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicingJ Biol Chem19912661811947119541711045
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• KarkkainenMJMakinenTAlitaloKLymphatic endothelium: a new frontier of metastasis researchNat Cell Biol200241E2E511780131
   PubMed Web of Science ®Google Scholar
• OlssonAKDimbergAKreugerJClaesson-WelshLVEGF receptor signalling – in control of vascular functionNat Rev Mol Cell Biol20067535937116633338
   PubMed Web of Science ®Google Scholar
• DjordjevicSDriscollPCTargeting VEGF signalling via the neuropilin co-receptorDrug Discov Today2013189–1044745523228652
   PubMed Web of Science ®Google Scholar
• Cebe-SuarezSZehnder-FjallmanABallmer-HoferKThe role of VEGF receptors in angiogenesis; complex partnershipsCell Mol Life Sci200663560161516465447
   PubMed Web of Science ®Google Scholar
• UlyattCWalkerJPonnambalamSHypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cellsBiochem Biophys Res Commun2011404377477921168388
   PubMed Web of Science ®Google Scholar
• Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-EyeDrugs R D20089426126918588357
   PubMed Web of Science ®Google Scholar
• EconomidesANCarpenterLRRudgeJSCytokine traps: multi-component, high-affinity blockers of cytokine actionNat Med200391475212483208
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• StewartMWWhat are the half-lives of ranibizumab and aflibercept (VEGF trap-eye) in human eyes? Calculations with a mathematical modelEye Rep20111e5
   Google Scholar
• ChristoforidisJBCarltonMMKnoppMVHinkleGHPET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit modelInvest Ophthalmol Vis Sci20115285899590321685343
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology2007114122179218218054637
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSSinghRJPharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology2007114585585917467524
   PubMed Web of Science ®Google Scholar
• EdelhauserHFRowe-RendlemanCLRobinsonMROphthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applicationsInvest Ophthalmol Vis Sci201051115403542020980702
   PubMed Web of Science ®Google Scholar
• SmelserGKIshikawaTPeiYFElectron Microscopic Studies of Intra-retinal Spaces: Diffusion of Particulate MaterialsIIStuggart, GermanySchattauer-Verlag1965
   Google Scholar
• TornquistPAlmABillAPermeability of ocular vessels and transport across the blood-retinal-barrierEye (Lond)19904Pt 23033092199237
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDBeyerJCPharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsRetina20072791260126618046235
   PubMed Web of Science ®Google Scholar
• AveryRLCastellarinAASteinleNCSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDBr J Ophthalmol201498121636164125001321
   PubMed Web of Science ®Google Scholar
• EYLEA™ (aflibercept) injection [US prescribing information]Tarrytown, NYRegeneron Pharmaceuticals, Inc2012
   Google Scholar
• HeierJSBrownDMChongVIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• SaishinYSaishinYTakahashiKVEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrierJ Cell Physiol2003195224124812652651
   PubMed Web of Science ®Google Scholar
• NorkTMDubielzigRRChristianBJPrevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primatesArch Ophthalmol201112981042105221825187
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMHafizGCLEAR-AMD 1 Study GroupA phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degenerationOphthalmology200611391522.e11522.e1416876249
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMBrowningDJA phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degenerationOphthalmology20091161121412148.e214119700196
   PubMed Web of Science ®Google Scholar
• HeierJSBoyerDNguyenQDCLEAR-IT 2 InvestigatorsThe 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosingOphthalmology201111861098110621640258
   PubMed Web of Science ®Google Scholar
• BrownDMHeierJSCiullaTCLEAR-IT 2 InvestigatorsPrimary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degenerationOphthalmology201111861089109721640257
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials Research Group; MartinDFMaguireMGFineSLRanibi-zumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• ParkUCShinJYMcCarthyLCPharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patientsMol Vis2014201680169425558172
   PubMed Web of Science ®Google Scholar
• KrebsIGlittenbergCAnsari-ShahrezaeiSHagenSSteinerIBinderSNon-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degenerationBr J Ophthalmol201397111443144623966368
   PubMed Web of Science ®Google Scholar
• LuxALlacerHHeussenFMJoussenAMNon-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBr J Ophthalmol200791101318132217537784
   PubMed Web of Science ®Google Scholar
• SuzukiMNagaiNIzumi-NagaiKPredictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degenerationBr J Ophthalmol20149891186119124711658
   PubMed Web of Science ®Google Scholar
• OtsujiTNagaiYShoKInitial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)Clin Ophthalmol201371487149023901256
   PubMedGoogle Scholar
• AmoakuWMChakravarthyUGaleRDefining response to anti-VEGF therapies in neovascular AMDEye (Lond)201529101397139826446737
   PubMed Web of Science ®Google Scholar
• ForooghianFCukrasCMeyerleCBChewEYWongWTTachyphylaxis after intravitreal bevacizumab for exudative age-related macular degenerationRetina200929672373119516114
   PubMed Web of Science ®Google Scholar
• EhlkenCJungmannSBohringerDAgostiniHTJunkerBPielenASwitch of anti-VEGF agents is an option for nonresponders in the treatment of AMDEye (Lond)201428553854524722504
   PubMed Web of Science ®Google Scholar
• YonekawaYAndreoliCMillerJBConversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degenerationAm J Ophthalmol201315612935.e2223668679
   PubMed Web of Science ®Google Scholar
• BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol201315611522.e1123706500
   PubMed Web of Science ®Google Scholar
• HoVYYehSOlsenTWShort-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitorsAm J Ophthalmol201315612328.e2223664153
   PubMed Web of Science ®Google Scholar
• KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
   PubMed Web of Science ®Google Scholar
• ChoHWeberMLShahCPHeierJSInitial utilization of aflibercept in exudative age-related macular degenerationEur J Ophthalmol201424457658124706352
   PubMed Web of Science ®Google Scholar
• ChangAALiHBroadheadGKIntravitreal aflibercept for treatment-resistant neovascular age-related macular degenerationOphthalmology2014121118819224144450
   PubMed Web of Science ®Google Scholar
• GharbiyaMIannettiLParisiFDe VicoUMungoMLMarencoMVisual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degenerationBiomed Res Int2014201427375424895562
   PubMed Web of Science ®Google Scholar
• GriffinDRRichmondPPOlsonJCIntravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and/or ranibizumab for neovascular age-related macular degenerationJ Ophthalmol2014201449717825505976
   PubMed Web of Science ®Google Scholar
• BroadheadGKHongTZhuMResponse of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degenerationRetina201535597598125627086
   PubMed Web of Science ®Google Scholar
• PatelKHChowCCRathodRRapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumabEye (Lond)2013275663667 quiz 66823558214
   PubMed Web of Science ®Google Scholar
• GrewalDSGillMKSarezkyDLyonATMirzaRGVisual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month resultsEye (Lond)201428789589924833178
   PubMed Web of Science ®Google Scholar
• SchachatAPSwitching anti-vascular endothelial growth factor therapy for neovascular age-related macular degenerationAm J Ophthalmol2013156112.e123791369
   PubMed Web of Science ®Google Scholar
• YannuzziLASorensonJSpaideRFLipsonBIdiopathic polypoidal choroidal vasculopathy (IPCV). 1990Retina201232Suppl 118
   Google Scholar
• SpaideRFYannuzziLASlakterJSSorensonJOrlachDAIndocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathyRetina19951521001107542796
   PubMed Web of Science ®Google Scholar
• WenFChenCWuDLiHPolypoidal choroidal vasculopathy in elderly Chinese patientsGraefes Arch Clin Exp Ophthalmol2004242862562915257461
   PubMed Web of Science ®Google Scholar
• CiardellaAPDonsoffIMHuangSJCostaDLYannuzziLAPolypoidal choroidal vasculopathySurv Ophthalmol2004491253714711438
   PubMed Web of Science ®Google Scholar
• DansinganiKNaysanJBalaratnasingamCFreundKEn Face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomographyRetina Epub8122015
   Web of Science ®Google Scholar
• BalaratnasingamCLeeWKKoizumiHDansinganiKKInoueMFreundKBPolypoidal choroidal vasculopathy: a distinct disease or manifestation of many?Retina Epub9232015
   Web of Science ®Google Scholar
• Gallego-PinazoRDolz-MarcoRGomez-UllaFMrejenSFreundKBPachychoroid diseases of the maculaMed Hypothesis Discov Innov Ophthalmol20143411111525756060
   PubMedGoogle Scholar
• HosokawaMShiragaFYamashitaASix-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathyBr J Ophthalmol20159981087109125712826
   PubMed Web of Science ®Google Scholar
• IjiriSSugiyamaKShort-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2015253335135725023147
   PubMed Web of Science ®Google Scholar
• YamamotoAOkadaAAKanoMOne-year results of intravitreal aflibercept for polypoidal choroidal vasculopathyOphthalmology Epub9162015
   Web of Science ®Google Scholar
• YamashitaMNishiTHasegawaTOgataNResponse of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumabClin Ophthalmol2014834334624591809
   PubMedGoogle Scholar
• MiuraMIwasakiTGotoHIntravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxisClin Ophthalmol201371591159523966764
   PubMedGoogle Scholar
• KoizumiHKanoMYamamotoAShort-term changes in chor-oidal thickness after aflibercept therapy for neovascular age-related macular degenerationAm J Ophthalmol2015159462763325555799
   PubMed Web of Science ®Google Scholar
• RuamviboonsukPTadaratiMVanichvaranontSHanutsahaPPokawattanaNPhotodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary studyBr J Ophthalmol20109481045105120530656
   PubMed Web of Science ®Google Scholar
• OguraYTerasakiHGomiFVIEW 2 InvestigatorsEfficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 studyBr J Ophthalmol2015991929725107900
   PubMed Web of Science ®Google Scholar
• HoangQVMendoncaLSDella TorreKEJungJJTsuangAJFreundKBEffect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injectionsOphthalmology2012119232132622054994
   PubMed Web of Science ®Google Scholar
• HoangQVTsuangAJGelmanRClinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapyRetina201333117918722990314
   PubMed Web of Science ®Google Scholar
• FreundKBHoangQVSarojNThompsonDIntraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumabOphthalmology201512291802181026025097
   PubMed Web of Science ®Google Scholar
• CurtisLHHammillBGSchulmanKACousinsSWRisks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degenerationArch Ophthalmol2010128101273127920937996
   PubMed Web of Science ®Google Scholar
• SemeraroFMorescalchiFDuseSGambicortiERomanoMRCostagliolaCSystemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overviewExpert Opin Drug Saf201413678580224809388
   PubMed Web of Science ®Google Scholar
• BraekkanSKHaldEMMathiesenEBCompeting risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso studyArterioscler Thromb Vasc Biol201232248749122075253
   PubMed Web of Science ®Google Scholar
• MangioneCMLeePPGutierrezPRSpritzerKBerrySHays RD; National Eye Institute Visual Function Questionnaire Field TestIDevelopment of the 25-item National Eye Institute Visual Function QuestionnaireArch Ophthalmol200111971050105811448327
   PubMed Web of Science ®Google Scholar
• YuzawaMFujitaKWittrup-JensenKUImprovement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degenerationOphthalmology2015122357157825439429
   PubMed Web of Science ®Google Scholar
• WijeyakumarWHongTBroadheadTLiHZhuMChangAAChanges in quality of life among patients treated with aflibercept for neovascular age-related macular degeneration (nAMD)Poster presented at: ARVO 2014 Annual Meeting AbstractsMay 6, 2014Orlando, FL
   Google Scholar
• VEGF Trap-Eye (aflibercept ophthalmic solution) Briefing Document Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259143.pdfAccessed November 17, 2015
   Google Scholar